LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $9 million in its third quarter. On a per-share basis, the Lexington, Massachusetts-based ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a ...

Analysts expect Voyager Therapeutics to report an earnings per share (EPS) of $-0.49. Investors in Voyager Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing ...

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.94 per share a year ago. These figures ...

SEC Filings provided by EDGAR Online, Inc.

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track ...

In a report released today, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on Align Tech (ALGN – Research Report), with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...